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Promising preclinical activity with agents blocking the function of vascular endothelial growth factor (VEGF) has been observed in
various cancer types, especially with combination therapy. However, these drugs decrease microvessel density, and it is not known
whether this reduced vessel density (VD) results in decreased delivery of concomitantly administered classical anticancer drugs. We
designed an in vivo study to investigate the relation between VEGF-blocking therapy, tumoral blood vessels, and intratumoral uptake
of anticancer drugs. Nude NMRI mice bearing colon adenocarcinoma (HT29) were treated with the anti-VEGFmAb A4.6.1 or
placebo. After 1 week, CPT-11 was administered 1h prior to killing the animals. In A4.6.1 treated tumours, there was a significant
decrease in VD, more pronounced with potentially functional large vessels than endothelial cords. Interestingly, a trend to increased
intratumoral CPT-11 concentration was observed (P¼0.09). In parallel, we measured an increase in tumour perfusion, as estimated
by high-performance liquid chromatography determination of intratumoural Hoechst 33342 concentration. In the growth delay study,
CPT-11 was at least equally effective with or without pretreatment with A4.6.1. These data suggest that tumour vascular function and
tumour uptake of anticancer drugs improve with VEGF-blocking therapy, and indicate the relevance for further investigations.
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Antiangiogenic therapy (AAT) inhibits new blood vessel formation
and decreases vessel density (VD) and tumour growth in several
tumour models (Kim et al, 1993; Borgstrom et al, 1998; Kamiya
et al, 1999; Lee et al, 2000; Soh et al, 2000; Beecken et al, 2001;
Shaheen et al, 2001). As a consequence, one would expect that
tumour blood flow and tumour oxygenation also decrease during
AAT. However, counterintuitive results have seemingly been
demonstrated in several settings. Hypoxia is unchanged or reduced
with squalamine (Teicher et al, 1998), the combination of TNP-470
and minocycline (Teicher et al, 1995b), and with the anti-VEGF
mAb A4.6.1 (Lee et al, 2000). In addition, interstitial fluid pressure
(IFP) is significantly reduced by the latter agent in the LS174T
colon carcinoma model (Lee et al, 2000). Conclusive data
concerning alterations in overall tumour perfusion after AAT are
lacking. One study with interleukin-12 as an antivascular agent
suggested decreased overall tumour perfusion (Gee et al, 2001). An
interesting new concept that AAT may normalise the established
tumour vasculature apart from inhibiting new vessel formation,
has emerged (Jain, 2001). This ‘normalisation’ could lead to better
tumour perfusion, oxygenation, and also to better delivery and
efficacy of therapeutic agents. Several studies have shown that AAT
potentiates the efficacy of standard anticancer drugs with
enhanced delay of tumour growth (Teicher et al, 1992, 1994;
Sweeney et al, 2001), stimulating interest in combining these two
treatment modalities. Also, low-dose (metronomic) regimens of
standard chemotherapy can have clear preclinical activity without
significant toxicity, and when combined with AAT may lead to full
and sustained regressions (Browder et al, 2000; Klement et al,
2000; Man et al, 2002). One study has suggested that pretreatment
with the antiangiogenic drug TNP-470 and minocycline results in
increased intratumoral drug levels of platinum (Teicher et al,
1995a). TNP-470 is a semisynthetic derivative of fumagillin, a
naturally occurring direct inhibitor of endothelial proliferation
(Ingber et al, 1990). Unfortunately, phase I studies with TNP-470
showed dose-limiting neurotoxicity with only minor tumour
response (Bhargava et al, 1999; Stadler et al, 1999; Logothetis
et al, 2001), and interest in using this drug clinically has
diminished. Antiangiogenic therapy increases tumour radiation
response, further supporting the new concept of ‘normalising
tumour vasculature’ (Gorski et al, 1999; Lee et al, 2000; Kozin et al,
2001). In these studies, AAT decreases rather than increases
hypoxia, explaining at least in part the increased radiosensitivity of
the tumour cells.
Vascular endothelial growth factor (VEGF) is a key growth
factor in the angiogenic process, and has a role in endothelial cell
migration, proliferation, vascular permeability, and endothelial cell
apoptosis. Inhibition of VEGF function by tyrosine kinase
inhibitors, or monoclonal antibodies against VEGF or one of its
receptors, has a significant antitumour effect. The monoclonal
VEGF antibody A4.6.1 significantly decreases VD, tumour growth,
and IFP, in several tumour models including colorectal cancer
(Kim et al, 1993; Borgstrom et al, 1998; Lee et al, 2000; Rowe et al,
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s2000). This monoclonal antibody with the product name
‘Bevacizumab’ has also shown promising clinical activity without
major toxicity in patients with metastatic renal cancer (Yang et al,
2002), and phase III clinical trials are ongoing. An increased
tumour radiation response has been observed with A4.6.1 (Lee
et al, 2000), but there are no data available regarding the effect of
the antibody on the tumour availability of anticancer drugs. In this
study, we have examined the effect of A4.6.1 on the intratumoral
availability of the cytotoxic CPT-11 in a colorectal cancer model.
Vascular function was evaluated after treatment using the
perfusion marker Hoechst 33342 (H33342). CPT-11 is a topoi-
somerase I inhibitor that is increasingly used in colon cancer, with
a biological half-life of about 1h in mice (Kaneda et al, 1990). A
prodrug, it is converted by decarboxylation in the liver into the
active metabolite SN-38, which is much more cytotoxic than the
parent compound. According to the paradigm of normalising
tumour vasculature with AAT, it is possible that delivery of CPT-11
is increased rather than decreased when given with VEGF-blocking
agents.
MATERIALS AND METHODS
Materials
The humanised murine antihuman VEGF mAb A. 4.6.1. was kindly
provided by Genentech (South San Francisco, CA, USA). CPT-11
was a gift from Aventis Pharma Belgium (Brussels, Belgium). CPT-
11 solution was freshly prepared in 0.9% saline at a concentration
of 10mgml
 1.
Tumour cell lines
The HT29 human colon cancer cell line was obtained from the
American Type Culture Collection (Manassas, VA, USA), and
cultured under 5% CO2 in minimal essential medium (MEM)
supplemented with 10% foetal bovine serum (FBS), 2Uml
 1
penicillin and streptomycin, 1mM sodium pyruvate, 2mML -
glutamine, and nonessential amino acids at 37%.
Tumour xenografts in nude mice and drug administration
Athymic male NMRI nude (nu/nu) mice, 6–8 weeks old, were
used. They were fed a diet of animal chow and water ad libitum
throughout the experiment. HT29 cells (1 10
6 cells in 100ml
phosphate-buffered saline (PBS) were injected subcutaneously in
the right and left flank of the animals. Tumour growth was
assessed every 2–3 days. Three orthogonal diameters were
measured with vernier callipers, and used to calculate the volume
of the tumour using the formula a b c p/6 (Tomayko and
Reynolds, 1989). When unilateral or bilateral tumours reached a
volume of 200–300mm
3, the mice were randomised into two
groups for the first part of the study, examining the intratumoral
CPT-11 concentration (20 tumours per group), and into four
groups for the second part of the study, examining the tumour
growth delay (10 tumours per group). A measure of 200mg A4.6.1,
diluted in saline, was administered intraperitoneally to each mouse
(day 0). The same dose was given on day 4. Control animals were
injected with saline. A single injection of 100mgkg
 1 CPT-11 was
administered intraperitoneally on day 7. This dose produces a
growth delay in our tumour model (data not shown), and is known
to be the LD0 in mice (Lavelle et al, 1996). Control animals were
injected with saline. Body weight, tumour volume, and time
between subcutaneous cell inoculation and randomisation were
not different in the various groups. The time between subcuta-
neous cell inoculation and randomisation was between 18 and 25
days. The mean was 23.6 days (treatment group) and 23.7 days
(control group) for the first part, and between 20.1 and 21.2 days
for the four groups in the second part. In the second part
measuring tumour growth delay, mice were sacrificed when the
largest tumour exceeded 1000mm
3. All the animal studies are in
agreement with the Guidelines for the Welfare of Animals in
Experimental Neoplasia (United Kingdom Co-ordinating Commit-
tee on Cancer Research (UKCCCR) 1998), and approved by the
Animal Ethics Committee of the Catholic University Leuven.
Tissue and blood sample preparation in the first part of the
study
The mice were killed at day 7 by ether inhalation one hour after the
CPT-11 injection. A 500ml blood sample was taken through an
intracardiac puncture and collected in an EDTA tube, and the
tumours were resected. Each tumour was halved, and one half was
frozen slowly in methylbutane for microscopic evaluation. The
other half was snap frozen in liquid nitrogen for the later
measurement of tumour CPT-11 concentrations. The blood was
centrifuged at 1500g for 10min in a swing-out rotor, and 100ml
supernatant plasma was removed and used to measure plasma
concentrations of CPT-11 and SN-38.
Histological analysis
Histological sections were stained for CD34 and CD105 with Biotin
conjugated CD34 and CD105 antibody (BD Biosciences), at a
dilution of 1:40, avidin–biotin complex, and diaminobenzidine as
chromogen. Vessel density was counted on CD34 and CD105
immunostained slides, according to conventional stereological
methods using an unbiased Gundersen counting frame (Gunder-
sen, 1978). Briefly, 10–20 quadrats per tumour were assessed,
selected via a stratified random sampling procedure at a
magnification of  200, with the aim of counting at least 50
vessels per tumour (Wildiers et al, 2002). The image was
unfocused while moving from one quadrat to another to avoid
any bias in vessel counting. Counting was performed in one
section through the largest diameter of the tumour. Vessels were
separated into endothelial cords, where no lumen or a lumen
smaller than 7mm (the size of an erythrocyte) was observed, and
into large vessels (lumen X7mm). In the large vessel group, the
shortest luminal diameter was measured and noted. The propor-
tion of tumour necrosis, expressed as a percentage, was estimated
at a magnification of  40. All measurements were performed by
two independent observers, with interobserver variability less than
10%, and all data were pooled for further analysis. Total VD,
endothelial cord VD, and large-vessel VD were calculated.
Determination of vascular function using the perfusion
marker H33342
The use of a fluorescent dye, H33342, to visualise and quantify
tumour functional vasculature when frozen sections are viewed
under ultraviolet light has been described (Smith et al, 1988; Quinn
et al, 1992). H33342 is frequently used as a perfusion marker in
preclinical research, where the vessels with surrounding stained
cells are usually counted microscopically (Thomas et al, 1996;
Bernsen et al, 1999; Bussink et al, 2000; Ljungkvist et al, 2002).
Although this analysis does not directly quantify the number of
perfused vessels, it provides an estimate of the relative degree of
perfused tumour vasculature. The results of this technique
correlated with tumour blood flow measurement using doppler
ultrasound in melanoma xenograft tumours (Goertz et al, 2002).
Hoechst 33342 was freshly prepared in 1ml physiological saline
per 100g body weight, and administered at 40mgkg
 1 intrave-
nously via the tail vein. The tumours were removed 1min after
dosing. Rather than count the number of H33342-labelled cells
microscopically, we decided to determine the global H33342
uptake in the tumour using HPLC. The same HPLC procedure as
for the CPT-11 measurements was used (cf. infra).
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A high-performance liquid chromatographic (HPLC) method was
used and validated for the simultaneous determination of CPT-11,
its metabolite SN-38, and H33342, in human plasma and tumour
tissue. Camptothecin (CPT) was used as an internal standard. As
sample pretreatment, 10ml of HPLC grade methanol was added to
50ml plasma together with 100ml internal standard solution. After
vortexing, the solution was heated to 401C for 15min. An
additional 200ml of triethylamine-acetate buffer was then added
to the solution, which was centrifuged at 14000r.p.m. for 5min.
Finally, the supernatant was filtered over a 0.2mm PVDF HPLC-
filter and 20ml was injected into the HPLC system. After
mechanical mixing of tumour tissue to generate emulsions of
cellular debris, a similar procedure was followed. Separation was
achieved on a Waters Symmetry 300 C8 reversed-phase column
(25cm 4.6, 5mm). The mobile phase consisted of 72% triethy-
lamine-acetate buffer (pH 5.2) and 28% acetonitrile at a flow rate
of 1.5mlmin
 1. CPT-11 and CPT were detected by fluorescence
with excitation and emission wavelengths of 369 and 424nm,
respectively. SN-38 and H33342 were detected by fluorescence with
respective excitation and emission wavelengths of 376 and 534nm.
The limits of quantitation for CPT-11, SN-38, and H33342 were 0.5,
0.25 and 0.5ngml
 1, respectively. Within-run and between-run
precisions were less than 10% and average accuracies were
between 90 and 110%.
Statistical analysis
‘Statistica 5.5’ was used for statistical analysis. Unless indicated,
Student’s t-test was used to evaluate differences between two
independent groups, and data are presented as mean7s.d. The
significance level was determined at 0.05. The tumour growth delay
calculations were based on the growth increase for a defined
period, the tumour volume reached at a defined time point, and
the time to grow from the starting volume to a higher defined
volume. Since the time points of interest varied for the several
questions posed, different parameters were used for the different
groups.
RESULTS
Anti-VEGF mAb does not impair intratumoral CPT-11
delivery
Pretreatment with anti-VEGF mAb produces a trend to higher
intratumoral availability of CPT-11; mean7s.d. 15.987
11.67mgg
 1 vs 10.9375.39mgg
 1 tumour tissue (P¼0.09)
(Figure 1). There was no difference in the mean plasma CPT-11
level in the two groups; 21.3178.03mgml
 1 in the anti-VEGF mAb
group and 19.37710.14mgml
 1 in the placebo group (P¼0.77).
The intratumoral levels of the active metabolite SN-38 were about
50 times smaller, with no significant difference between the anti-
VEGF mAb group (0.2670.10mgg
 1) and the placebo group
(0.2470.09mgg
 1)( P¼0.49). The mean tumour volume at day 7,
the time of excision, was significantly lower (Po0.001) in the anti-
VEGF mAb-treated group (3557123mm
3) compared to the
placebo group (4927113mm
3).
Anti-VEGF mAb reduces tumour VD
At 1 week after the first treatment with anti-VEGF mAb, total VD
decreased significantly by 20.1% on CD34 slides and 26.4% on
CD105 slides (Table 1). The large-vessel VD decreased by 53.4 and
52.1% on CD34 and CD105 slides, respectively. The vessel diameter
of large vessels was decreased to a lesser but significant extent after
anti-VEGF mAb, by 19.2 and 21.1%, respectively. Total and
endothelial cord VD were lower on CD105 than on CD34 slides. In
contrast, large-vessel VD was more than twice as high after CD105
compared to CD34 staining, which was confirmed by the two
independent observers. There was no difference in the estimated
necrosis of tumours treated with anti-VEGF mAb (37717.6%) or
placebo (34.5721.9%) (P¼0.69). An example of histological
sections of anti-VEGF mAb and placebo-treated tumours is shown
(Figure 2).
Tumour growth delay
There was progressive growth of HT29 tumours up to volumes of
1000mm
3. Anti-VEGF mAb retarded growth significantly, with a
mean tumour growth delay of 8 days. CPT-11 as a single bolus LD0
dose, resulted in only a moderate growth delay of about 2–3 days,
which was not altered when CPT-11 was administered after
pretreatment with anti-VEGF mAb (Figure 3; Table 2).
Determination of vascular function using the perfusion
marker H33342
Five of the 40 tumour samples, were excluded due to analytical
error. The intratumoral H33342 concentration was 57% higher in
the anti-VEGF-mAb-treated group (n¼16) than in the placebo
group (n¼19) (P¼0.01) (Figure 1).
DISCUSSION
Anti-VEGF mAb does not impair intratumoral CPT-11
delivery
For any cancer treatment to be successful, it needs to meet at least
two major criteria. Firstly, it must be potent and effective in
destroying or inhibiting cancer cells in vivo, and this must be
achieved with acceptable toxicity to normal host tissues. Hence, it
must be possible to deliver the drug in vivo into the tumour tissue
in sufficiently high concentrations. Different barriers to successful
drug delivery have been recognised, as highlighted by Jain (1994,
1997, 1998). The chaotic blood supply, the quality of the vessel
wall, and the interstitium can all play a major role in preventing
efficient drug delivery (Jain, 1987). Antiangiogenic therapy can
interfere significantly with these three factors, but studies of the
impact of AAT on the delivery of concomitant cytotoxic drugs are
very sparse.
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Figure 1 After anti-VEGF mAb therapy, large-vessel VD decreases
(P¼0.03) while intratumoral H33342, injected 1min before killing as
indicator of tumour perfusion, increases (P¼0.01). There is a trend to
higher intratumoral concentration of CPT-11 in the anti-VEGF-mAb-
treated group (P¼0.09). Asterisks, Po0.05 vs placebo. Data indicate
mean7s.e.
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sOur investigation aimed to study this question, and to
quantitatively evaluate the importance of the tumour perfusion
as the first barrier. This in turn raised the question of whether VD
per se could be a predictive tool for tumour uptake of cytotoxic
drugs. Our results clearly show that anti-VEGF mAb definitely
does not impair, and may even improve intratumoral uptake of
CPT-11 in this tumour model. This is remarkable because anti-
VEGF mAb clearly decreases tumour VD in this model. These data
are consistent with our previous work where we showed a lack of
correlation between melphalan tumour uptake and VD (Wildiers
et al, 2002). A plausible explanation might be that although fewer
vessels are present, they are of better quality, likely allowing
improved delivery of bloodborne agents. The counting of vessels
does not seem to reflect their perfusion status. Many tumour
vessels are only perfused temporarily (Chaplin and Hill, 1995), or
sometimes not at all (Vajkoczy et al, 2000). In addition to vascular
length, tissue perfusion is determined by mean vessel diameter,
flow resistance, and erythrocyte velocity (Intaglietta and Zweifach,
1974; Leunig et al, 1992; Baish et al, 1996; Vajkoczy et al, 1998). We
correlated our data with measurement of functional vasculature,
indicating a 57% increase in intratumoral perfusion after anti-
VEGF mAb treatment, consistent with the trend of increased
tumour CPT-11 uptake. Our data support the proposed concept of
‘normalising’ tumour vasculature with AAT (Jain, 2001). Pruning
of immature and inefficient blood vessels by eliminating excess
endothelial cells could result in a more ‘normal’ vasculature, which
is better equipped to deliver nutrients and therapeutic agents. It
seems plausible that the above-mentioned phenomenon is an
important mechanism for the observed increased CPT-11 uptake,
but other known and unknown mechanisms might be involved and
are discussed below.
Apart from tumour perfusion (the ‘first’ barrier), also vascular
permeability (the ‘second’ barrier) could theoretically play a role in
the delivery of anticancer agents. In general, the microvasculature
of solid tumours is hyperpermeable to macromolecules in
comparison to normal vessels. This is presumably due to
Table 1 Effect of anti-VEGF mAb on tumor vessel density (VD)
Anti-VEGF (n¼20) Placebo (n¼20) P Difference (%)
CD34-stained sections
Total VD (n per mm
2) 36.573.3
a 45.772.4 0.027* 20.1
Endothelial cords VD (n per mm
2) 34.673.2 41.672.4 0.08 16.8
Large vessel VD (n per mm
2)
b 1.9070.38 4.0870.88 0.029* 53.4
Vessel diameter (mm) 14.370.69 17.770.56 o0.001* 19.2
CD105-stained sections
Total VD (n per mm
2) 29.072.4 39.472.2 0.0026* 26.4
Endothelial cords VD (n per mm
2) 24.972.4 30.872.3 0.078 19.1
Large vessel VD (n per mm
2) 4.1270.58 8.6071.1 0.001* 52.1
Vessel diameter (mm) 12.770.44 16.170.37 o0.001* 21.1
aMean7s.e.
bLarge vessels indicate vessels with a shortest luminal diameter larger than the size of an erythrocyte (47mm).
Significant at level o0.05.
AB
CD
Figure 2 CD34 (A, B) and CD105 (C, D) staining of colorectal
tumours shows decreased VD in tumours treated with anti-VEGF mAb
(A, C) vs placebo (B, D). Original magnification  200.
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Figure 3 Effect of anti-VEGF mAb, CPT-11, and the combination of anti-
VEGF mAb and CPT-11 on the growth of HT29 colonic tumours in mice
(n¼10 per group). (A) Mean tumour growth. The growth curve of each
subgroup was terminated when one mouse in that subgroup developed a
tumour of 1000mm
3, to avoid nonrepresentative mean growth curves.
Data points indicate the mean7s.e. (B) The individual growth curves of
different subgroups.
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sinteractions between vascular endothelial cells and VEGF, also
known as the vascular permeability factor (VPF). It has been
demonstrated that tumour vascular permeability can be reduced
by neutralization of endogenous VEGF with the anti-VEGF mAb
A4.6.1 (Yuan et al, 1996). Although VEGF increases vascular
permeability, our data do not suggest that blocking VEGF
decreases permeability to CPT-11, as delivery was improved rather
than diminished. Vascular permeability is probably more im-
portant for large molecules (Teicher et al, 1995b), and less so for
small molecules (Wildiers et al, 2002) such as CPT-11 and SN-38,
which have molecular weights of 586 and 392gmol
 1, respectively.
In short, changes in vessel permeability do not seem to play a
major role in the observed increased uptake of CPT-11.
Also interstitial transport (the ‘third’ barrier) could play a role
in the intratumoral availability of small drugs such as CPT-11. The
uniformly elevated interstitial fluid pressure in solid tumours leads
to negligible convection in the tumour interstitium (Boucher et al,
1990), and drug delivery through the extracellular matrix (ECM)
relies on passive diffusive transport (Netti et al, 1999). This
transport is influenced by the constituents and characteristics of
the ECM (Pluen et al, 2001). Interstitial pressure decreases by 74%
in the LS174T colorectal cancer tumour model after pretreatment
with A4.6.1 (Lee et al, 2000). It is therefore also possible that
decreased interstitial fluid pressure allows convection again to a
certain degree, leading to better delivery despite a decreased
number of vessels.
Since necrosis can be expected to influence the intratumoral
uptake of drugs such as CPT-11, we estimated the amount of
necrosis in each tumour. Anti-VEGF mAb does not influence the
amount of necrosis in this tumour type, and this aspect can
therefore not explain the differences in the results we obtained on
intratumoral availability of CPT-11.
Since intratumoral pH seems an important but relatively little
studied parameter influencing drug uptake and resistance (Simon,
1999), pH alterations after anti-VEGF mAb could have influenced
CPT-11 and SN-38 uptake. CPT-11 has a very complex pharma-
cology, and is known in two forms, an active lactone form and an
inactive carboxylate form, between which a pH-dependent
equilibrium exists that significantly impacts on the kinetic profile
of the compound (Gelderblom et al, 1999; Mathijssen et al, 2001).
The uptake of CPT-11 and SN-38 by intestinal cells has been
demontrated to be clearly pH sensitive. At physiological pH, the
uptake rates of CPT-11 and SN-38 decreased significantly by 65%
at pH greater than 6.8, and accordingly, uptake rates of both
lactones were significantly higher than those of their carboxylates
(Kobayashi et al, 1999). Moreover, a decreased uptake of SN-38
with increasing pH correlated with a smaller cytotoxic effect. To
our knowledge, the effect of anti-VEGF therapy on tumour pH and
its correlation with uptake of anticancer drugs has not been
consistently studied, and is a very interesting domain for further
research.
The trend in increased intratumoral availability was only
identified with the abundant parent compound CPT-11, and not
for SN-38. There is no clear explanation for this at the moment;
however, some remarks can be considered. Intratumoral SN-38
was only measurable at concentrations 50 times lower than CPT-
11. It is known that only a limited amount of CPT-11 is
transformed into SN-38 (Chabot, 1997), which agrees with plasma
levels being about 12 times lower than CPT-11 in our study (data
not shown). Intratumoral SN-38 levels were somewhat higher after
anti-VEGF therapy, but not significantly. These results are thus not
really contradictory with the CPT-11 findings.
The measurements of CPT-11 only represent concentrations in
the whole tumour, not only tumour cells, but also blood vessels
and the interstitium. It was not possible to distinguish differences
in CPT-11 concentrations within the different compartments in the
present study. Plasma and red blood cells in the tumoral vessels
also contain CPT-11 (Combes et al, 2000), and it is therefore
possible that differences in intratumoral blood volume, secondary
to AAT, may be a factor. However, blood vessels comprise only
about 7% of the total tumour volume in this model (from a
random sample of four tumours, data not shown), and about 91%
of the vessels counted were endothelial cords without a lumen
(Table 1). Assuming the volume of blood in the tumour is 5%
(probably an overestimate), then 20ml will be present in a tumour
of 400mm
3 (400ml). With a plasma concentration of 20mgml
 1
and with approximately 40% of CPT-11 present in erythrocytes,
tumoral blood only contains 0.4mg of a total tumour concentration
of 4mg. Therefore, at most 10% of the intratumoral CPT-11 is
derived from blood, and this amount will not greatly affect the
measurements.
Anti-VEGF mAb reduces tumour VD
As anti-VEGF mAb inhibits the formation of new blood vessels, it
is logical that tumour VD decreases. However, most investigators
have looked at total VD, which in some tumour types is
predominantly determined by endothelial cords that presumably
Table 2 Effect of CPT-11 and anti-VEGFmAb on tumour growth parameters
Effect of anti-VEGFmAb on tumour growth Anti-VEGF Placebo P
Start volume at day 0 (start of anti-VEGFmAb or placebo) 24279.8
a 244711.2
Growth increase from day 0 to day 10 (multiplication factor) 1.9170.13 3.0870.26 0.0009*
Tumour volume at day 10 (mm
3) 458729 766791 0.005*
Time to grow from 250 to 900mm
3 (days) 21.571.37 13.671.65 0.00007*
Effect of CPT-11 on tumour growth CPT-11 Placebo P
Start volume at day 7 (start of CPT-11 or placebo) 502770 527754
Growth increase from day 7 to day 10 (multiplication factor) 1.2170.03 1.4670.10 0.04*
Tumour volume at day 14 (mm
3)
b 660755 840759 0.04*
Time to grow from volume 500 to 900mm
3 (days) 8.7371.28 6.6171.04 0.12
Effect of CPT-11 after anti-VEGFmAb on tumour growth Anti-VEGF+CPT-11 Anti-VEGF P
Start volume at day 7 (start of CPT-11 or placebo) 407730 391724
Growth increase from day 7 to day 17 (multiplication factor) 1.4670.10 1.7870.08 0.02*
Tumour volume at day 17 (mm
3) 599761 702765 0.27
Time to grow from volume 400 to 700mm
3 (days) 11.3572.9 8.7672.28 0.04*
aMean7s.e.
bn¼7 in both groups. *Significant at level o0.05.
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splay only a minor role in the delivery and transport of nutrients
and drugs, as there is no lumen present. We have found that VEGF
mAb diminishes more the number of larger vessels than of
endothelial cords in this HT29 human xenograft colorectal
tumour model. This effect could be due to inhibition of larger
vessel formation, or to a decrease in size of existing larger
vessels. In the setting of drug delivery, and in view of transport
capacity, it is important to assess the role of large vessels
specifically.
To evaluate vasculature on tumour sections, various antibodies
to endothelial cells (EC) are available. CD34 is one of the classical
targets to identify EC, and has been called a ‘panendothelial’
marker. CD105 or endoglin is a more recently recognised
endothelial antigen that is strongly expressed on proliferating
EC, but little or not on resting EC. Therefore, CD105 represents a
powerful marker of neovascularisation (Fonsatti et al, 2000, 2001).
Blood vessel counts using CD105 are a better prognostic factor
than CD34 in patients with breast cancer (Kumar et al, 1999). The
vessel counts of endothelial cords, representing the majority of
vessels counted, are lower with CD105 than with CD34 staining. In
contrast, large-vessel VD, which reflects potentially perfused
vessels, was more than twice as high with CD105 than with
CD34 staining. It is known that CD34 expression on endothelial
cells can be downregulated during proliferation, and endothelial
cells of larger veins have been reported to be CD34 negative (Delia
et al, 1993; Muller et al, 2002). Our data confirm these
observations, and suggest that CD105 staining is necessary to
assess large vessels.
Tumour growth delay
The enhanced antitumour effect of chemotherapeutic agents when
combined with AAT (Teicher et al, 1992, 1994; Sweeney et al,2 0 0 1 )
is probably not only due to differences in vascularisation, perfusion
and drug delivery, but also an increase in tumour cell apoptosis
(Kamiya et al, 1999; Wassberg et al, 1999). VEGF is a recognised
chemoprotectant, particularly for drugs that inhibit microtubules,
by reducing the proapoptotic effect of chemotherapy (Tran et al,
2002). Inhibiting proangiogenic factors such as VEGF with AAT
may make endothelial cells more sensitive to cytotoxic agents.
The tumour growth delay with anti-VEGF mAb confirms
previous observations in colon cancer and other tumour models
(Lee et al, 2000). It must be emphasised that anti-VEGF mAb was
administered only twice for the specific purpose of this study, and
prolonged administration would probably result in longer growth
delays. Similarly, CPT-11 was administered only as a single LD0
bolus. Higher response rates and increased tumour growth
inhibition have been reported with fractionated regimens in mice,
for example, every 4 days for 3 cycles (Lavelle et al, 1996), 6-day
courses (O’Leary et al, 1999), or at low doses (10mgkg
 1)i n
protracted schedules of several weeks (Houghton et al, 1995),
administering a higher total dose. Regardless, CPT-11 retards
tumour growth with or without anti-VEGF mAb pretreatment, and
our data certainly do not show antagonism between CPT-11 and
anti-VEGF mAb. The anti-VEGF mAb þ CPT-11 group grew
faster from day 0 to day 7, in comparison with the anti-VEGF mAb
alone group (Figure 3), but not significantly (P¼0.68). Never-
theless, following CPT-11 administration to the former group at
day 7, the growth curves clearly cross, indicating effective growth
inhibition in this subgroup.
It is also interesting that a clear antiangiogenic effect of CPT-11,
separate from the antitumour cell effect, has been reported
(O’Leary et al, 1999). The study period allowing only 1h exposure
to CPT-11 was too short to evaluate this effect.
It is remarkable that the anti-VEGF mAb A4.6.1 substantially
reduces, but does not completely suppress, tumour growth after
systemic administration. The main mechanism of action is
probably blockade of human VEGF (VEGF 165) in the xenograft
tumours. However, it has been shown that host VEGF (VEGF 164
in mice) can also significantly contribute to tumour growth
(Gerber et al, 2000). For maximum inhibition of tumour growth in
human xenograft tumour models in mice, it is probably necessary
to block VEGF completely.
Determination of vascular function using the perfusion
marker H33342
H33342 is used as an index of functional vascular volume, and
quantified with a random sampling procedure using the Chalkley
method on histological slides (Smith et al, 1988; Quinn et al, 1992).
However, the detection of all the H33342 in the tumour may be a
more global index of whole tumour perfusion. Using the same HPLC
conditions as for CPT-11 and SN-38, we were able to detect and
quantify H33342 as a distinct peak on the chromatogram. This
concentration reflects the global uptake of H33342, but can be
altered by many physiological parameters including blood flow,
permeability, blood pressure, and interstitial pressure. It is a
recognised relative rather than an absolute index of perfusion and
functional vasculature, allowing comparison between different
treatments in tumour models. This approach is original, objective,
and feasible when HPLC technology is available. H33342 is
vasoactive at doses above 10mgkg
 1 (Trotter et al, 1990). However,
the validity of the data is not affected, as such an effect would only
be expected to influence absolute, but not relative, uptake. The
uptake in treated tumours was compared to that of controls.
In summary, our results show that the anti-VEGF mAb tends to
improve CPT-11 delivery, and this corresponds to an increase in
tumour perfusion, even though VD is significantly decreased. This
increased perfusion is a plausible cause of the observed increase in
CPT-11 uptake, although other phenomena might be involved.
Interestingly, the tumour growth delay induced by the combina-
tion of anti-VEGF mAb and CPT-11 is at least additive. Tumour
VD lacks predictive power for intratumoral delivery of anticancer
drugs. Immunohistological staining of endothelial cells with CD34
and CD105, and the separation of endothelial cord and large vessel
densities, provide additional information on tumour vascularisa-
tion. A new index of functional vasculature and perfusion using
HPLC determination of intratumoral H33342 is described, allowing
comparison of different treatments in tumour models.
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